
TY  - JOUR
TI  - Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 111
IS  - S1
SN  - 1464-4096
UR  - https://doi.org/10.1111/bju.12069
DO  - doi:10.1111/bju.12069
SP  - 13
EP  - 119
PY  - 2013
ER  - 

TY  - JOUR
TI  - Letter to the Editor
JO  - European Journal of Haematology
VL  - 42
IS  - 4
SN  - 0902-4441
UR  - https://doi.org/10.1111/j.1600-0609.1989.tb01232.x
DO  - doi:10.1111/j.1600-0609.1989.tb01232.x
SP  - 405
EP  - 414
PY  - 1989
ER  - 

TY  - JOUR
C7  - e27455
TI  - SIOP ABSTRACTS
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 65
IS  - S2
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.27455
DO  - doi:10.1002/pbc.27455
SP  - e27455
PY  - 2018
ER  - 

TY  - JOUR
TI  - AASLD Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 58
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.26727
DO  - doi:10.1002/hep.26727
SP  - 208A
EP  - 1309A
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 17
IS  - S2
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14155
DO  - doi:10.1111/ajt.14155
SP  - 11
EP  - 92
PY  - 2017
ER  - 

TY  - JOUR
TI  - Wednesday July 5, 2006 17:30–19:00 Hall 1 Schwarz Pharma & Valeant Pharmaceuticals International Satellite Symposium What's around the corner: AEDs in late development
JO  - Epilepsia
VL  - 47
IS  - s3
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2006.00715_90.x
DO  - doi:10.1111/j.1528-1167.2006.00715_90.x
SP  - 272
EP  - 272
PY  - 2006
AB  - 1 E. Ben-Menachem ( 1 Neurologkliniken, Sahlgrenska Universitetssjukhuset, Goteberg, Sweden ) Lacosamide is in Phase 3 of clinical development for the adjunctive treatment of epilepsy and neuropathic pain. Currently the mode of action (MOA) is under investigation since it has been previously demonstrated that lacosamide does not share a MOA with other currently marketed antiepileptic drugs (AEDs). The drug can be administered orally or intravenously. Results from pharmacokinetic studies suggest that lacosamide has a low potential for drug-drug interactions, and it appears that lacosamide has a minimal risk for affecting the pharmacokinetics of commonly prescribed concomitant AEDs for the treatment of epilepsy. In a double-blind, randomized, placebo-controlled, multicenter trial for the treatment of partial seizures (SP667), lacosamide was administered orally in doses of 200 mg, 400 mg and 600 mg divided in 2 daily doses. In this trial, lacosamide demonstrated a statistically significant reduction in seizure frequency over placebo. Moreover, the 50% responder rate (defined as patients with at least a 50% reduction in seizure frequency) was statistically significant. A further trial (SP616) investigated the safety, tolerability and pharmacokinetics of IV lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. The nature of AEs reported following 60- and 30 minute infusions of lacosamide was consistent with AEs reported following oral administration of lacosamide. Dose-related adverse events include dizziness, nausea, fatigue, ataxia, vision abnormal, diplopia, and nystagmus. The currently available results justify the further development of lacosamide for the treatment of epilepsy.
ER  - 

TY  - JOUR
AU  - Chen, Guo-Dong
AU  - Lai, Xing-Qiang
AU  - Ko, Dicken Shiu-Chung
AU  - Qiu, Jiang
AU  - Wang, Chang-Xi
AU  - Han, Ming
AU  - Li, Jun
AU  - Huang, Gang
AU  - He, Xiao-Shun
AU  - Chen, Li-Zhong
TI  - Comparison of efficacy and safety between rabbit anti-thymocyte globulin and anti-T lymphocyte globulin in kidney transplantation from donation after cardiac death: A retrospective cohort study
JO  - Nephrology
JA  - Nephrology
VL  - 20
IS  - 8
SN  - 1320-5358
UR  - https://doi.org/10.1111/nep.12469
DO  - doi:10.1111/nep.12469
SP  - 539
EP  - 543
KW  - anti-T lymphocyte globulin
KW  - donation after cardiac death
KW  - kidney transplantation
KW  - rabbit anti-thymocyte globulin
PY  - 2015
AB  - Abstract Aim To compare the efficacy and safety between rabbit anti-thymocyte globulin (Thymoglobulin) and anti-T lymphocyte globulin (ATG-Fresenius, ATG-F) in donation after cardiac death (DCD) kidney transplantation. Methods We retrospectively analyzed 255 cases of DCD kidney transplantation performed at our hospital from February 2007 to October 2013. The patients were divided into two groups based on their induction therapies with Thymoglobulin (n?=?188) or ATG-F (n?=?67). Clinical data were collected and compared between the two groups. Results Delayed graft function (DGF) occurred in 36 (19.1%) patients in the Thymoglobulin group versus 17 (25.4%) patients in the ATG-F group (P?=?0.281). However, if we subgroup the patients with increased risk factors for DGF, the DGF rate was 9/40 (22.5%) in the Thymoglobulin group versus 9/16 (56.3%) in the ATG-F group (P?=?0.015). Duration of DGF was significantly shorter in the Thymoglobulin group (11.7 days vs. 16.1 days). The acute rejection rate was significantly lower in the Thymoglobulin group (9.6% vs. 19.4%, P?=?0.035). One-year graft and patient survival were both comparable between the Thymoglobulin and ATG-F groups. The adjusted odds ratio of DGF was 4.283 (1.137?16.13) between the ATG-F and Thymoglobulin groups in patients with increased risk factors for DGF. Conclusion Compared with ATG-F, Thymoglobulin may reduce duration of DGF and acute rejection rate after DCD kidney transplantation. Moreover, Thymoglobulin significantly reduced DGF in patients with increased risk factors for DGF.
ER  - 

TY  - JOUR
TI  - Abstracts PDS
JO  - Allergy
JA  - Allergy
VL  - 74
IS  - S106
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.13959
DO  - doi:10.1111/all.13959
SP  - 130
EP  - 331
PY  - 2019
ER  - 

AU  - Smith, Ann C.M.
AU  - Gropman, Andrea
C7  - pp. 739-768
TI  - Smith-Magenis Syndrome
SN  - 9780470191415
UR  - https://doi.org/10.1002/9780470893159.ch50
DO  - doi:10.1002/9780470893159.ch50
SP  - 739-768
KW  - Smith-Magenis syndrome
KW  - mental retardation
KW  - de novo interstitial deletion
KW  - heterozygous mutations
KW  - laryngeal abnormalities
PY  - 2019
AB  - Summary This chapter contains sections titled: Introduction Manifestations and Management Dedication Resources
ER  - 

TY  - JOUR
TI  - Speaker Abstracts
JO  - Child: Care, Health and Development
VL  - 36
IS  - s1
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1365-2214.2009.01058.x
DO  - doi:10.1111/j.1365-2214.2009.01058.x
SP  - 5
EP  - 38
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Session 1, Sunday 13 September
JO  - European Journal of Neurology
VL  - 16
IS  - s3
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1468-1331.2009.02821.x
DO  - doi:10.1111/j.1468-1331.2009.02821.x
SP  - 55
EP  - 334
PY  - 2009
ER  - 

TY  - JOUR
TI  - Plenary Paper Session
JO  - Journal of the American Geriatrics Society
VL  - 59
IS  - s1
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1532-5415.2011.03416.x
DO  - doi:10.1111/j.1532-5415.2011.03416.x
SP  - S1
EP  - S232
PY  - 2011
ER  - 

TY  - JOUR
TI  - ISAD 2014, 8th Georg Rajka Symposium on Atopic Dermatitis, Nottingham, 21–23 May 2014
JO  - British Journal of Dermatology
JA  - Br J Dermatol
VL  - 170
IS  - 6
SN  - 9780470191415
UR  - https://doi.org/10.1111/bjd.13064
DO  - doi:10.1111/bjd.13064
SP  - e1
EP  - e55
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 109
IS  - S2
SN  - 9780470191415
UR  - https://doi.org/10.1111/vox.12359
DO  - doi:10.1111/vox.12359
SP  - 1
EP  - 96
PY  - 2015
ER  - 

TY  - JOUR
TI  - Poster Discussion Sessions
JO  - Allergy
VL  - 65
IS  - s92
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1398-9995.2010.02392.x
DO  - doi:10.1111/j.1398-9995.2010.02392.x
SP  - 78
EP  - 208
PY  - 2010
ER  - 

TY  - JOUR
TI  - ABSTRACTS – Symposium
JO  - International Journal of Rheumatic Diseases
VL  - 11
IS  - s1
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1479-8077.2008.00374.x
DO  - doi:10.1111/j.1479-8077.2008.00374.x
SP  - A1
EP  - A83
PY  - 2008
ER  - 

TY  - JOUR
TI  - Short Communications
JO  - European Journal of Neurology
VL  - 18
IS  - s2
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1468-1331.2011.03550.x
DO  - doi:10.1111/j.1468-1331.2011.03550.x
SP  - 20
EP  - 65
PY  - 2011
ER  - 

TY  - JOUR
TI  - Immunology, rheumatology
JO  - European Journal of Clinical Investigation
VL  - 35
IS  - s2
SN  - 9780470191415
UR  - https://doi.org/10.1111/j.1365-2362.2005.1478_5.x
DO  - doi:10.1111/j.1365-2362.2005.1478_5.x
SP  - A79
EP  - A87
PY  - 2005
ER  - 

TY  - JOUR
AU  - Kim, Miji
AU  - Basharat, Anam
AU  - Santosh, Ramchandani
AU  - Mehdi, Syed F.
AU  - Razvi, Zanali
AU  - Yoo, Sun K.
AU  - Lowell, Barbara
AU  - Kumar, Amrat
AU  - Brima, Wunnie
AU  - Danoff, Ann
AU  - Dankner, Rachel
AU  - Bergman, Michael
AU  - Pavlov, Valentin A.
AU  - Yang, Huan
AU  - Roth, Jesse
C7  - e3072
C8  - DMRR-18-REV-219.R1
TI  - Reuniting overnutrition and undernutrition, macronutrients, and micronutrients
JO  - Diabetes/Metabolism Research and Reviews
JA  - Diabetes Metab Res Rev
VL  - 35
IS  - 1
SN  - 9780470191415
UR  - https://doi.org/10.1002/dmrr.3072
DO  - doi:10.1002/dmrr.3072
SP  - e3072
KW  - infectious diseases
KW  - micronutrients
KW  - obesity
KW  - obesity paradox
KW  - overnutrition
KW  - undernutrition
PY  - 2019
AB  - Summary Over-nutrition and its late consequences are a dominant theme in medicine today. In addition to the health hazards brought on by over-nutrition, the medical community has recently accumulated a roster of health benefits with obesity, grouped under ?obesity paradox.? Throughout the world and throughout history until the 20th century, under-nutrition was a dominant evolutionary force. Under-nutrition brings with it a mix of benefits and detriments that are opposite to and continuous with those of over-nutrition. This continuum yields J-shaped or U-shaped curves relating body mass index to mortality. The overweight have an elevated risk of dying in middle age of degenerative diseases while the underweight are at increased risk of premature death from infectious conditions. Micronutrient deficiencies, major concerns of nutritional science in the 20th century, are being neglected. This ?hidden hunger? is now surprisingly prevalent in all weight groups, even among the overweight. Because micronutrient replacement is safe, inexpensive, and predictably effective, it is now an exceptionally attractive target for therapy across the spectrum of weight and age. Nutrition-related conditions worthy of special attention from caregivers include excess vitamin A, excess vitamin D, and deficiency of magnesium.
ER  - 

TY  - JOUR
TI  - Poster session abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr. Pulmonol.
VL  - 16
IS  - S9
SN  - 9780470191415
UR  - https://doi.org/10.1002/ppul.1950160706
DO  - doi:10.1002/ppul.1950160706
SP  - 203
EP  - 298
PY  - 1993
ER  - 
